Menu Search
Equities

Chemomab Therapeutics Ltd

2QV0:DUS

Chemomab Therapeutics Ltd

Actions
  • Price (EUR)1.51
  • Today's Change0.04 / 2.72%
  • Shares traded2.00k
  • 1 Year change+60.64%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 18:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-15.00m
  • Incorporated2011
  • Employees20.00
  • Location
    Chemomab Therapeutics LtdKiryat Atidim, Building 7TEL AVIV-YAFO 6158002IsraelISR
  • Phone+972 773310156
  • Websitehttps://www.chemomab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.